Lifecore's Third-Quarter Loss Balloons To $40.1 Million On A $31.3 Million Debt Derivative Charge

Revenue fell 18.6% to $25.3 million, while adjusted EBITDA rose to $4.0 million as operating expenses dropped 28.9%.

Share
Lifecore's Third-Quarter Loss Balloons To $40.1 Million On A $31.3 Million Debt Derivative Charge

Lifecore Biomedical, a contract manufacturer of sterile injectable drugs, reported a third-quarter net loss of $40.1 million, or $1.08 per share, against a $10.0 million loss a year earlier. A $31.3 million charge tied to a related-party debt derivative accounts for most of it, the company said in an 8-K filed Wednesday.

A paper charge, shrinking sales

The charge is the change in fair value of a debt derivative liability owed to a related party. It compares with $0.4 million in the year-earlier quarter. The liability on the balance sheet stood at $62.2 million at September 30, against $26.6 million at the end of December 2025.

Revenue fell 18.6% to $25.3 million from $31.1 million. Contract development and manufacturing sales were $17.8 million and hyaluronic acid manufacturing sales were $7.5 million. For the first nine months, revenue was $82.7 million, down 21.8%, and the net loss was $61.2 million, or $1.70 per share.

Gross profit slipped to $6.8 million from $7.8 million. The operating loss narrowed to $0.9 million from $3.1 million.

Costs cut, EBITDA up

Operating expenses dropped 28.9% to $7.7 million. Adjusted EBITDA, a profit measure that excludes items such as the derivative charge, rose to $4.0 million from $3.1 million. For nine months it was $13.6 million, down from $21.1 million.

Free cash flow for the nine months was $6.9 million, from cash operations of $9.5 million. Liquidity at quarter end was about $38.0 million: $23.0 million in cash plus $15.0 million of revolving credit available.

Related-party long-term debt rose to $154.5 million from $135.6 million at the end of December 2025. Interest expense on that debt was $7.7 million in the quarter.

New programs, pending merger

Lifecore, based in Chaska, Minnesota, develops, fills and manufactures injectables and makes pharmaceutical-grade hyaluronic acid. CEO Paul Josephs said it won two technology transfer projects in the quarter, one for a biotech's new drug application and one for a marketed product at a large pharmaceutical company. "We expect each to contribute to the company's long-term revenue growth objectives, beginning in 2027," he said.

Early in the fourth quarter, Josephs said, Lifecore also secured three development-phase programs: one Phase 2 product with a top-20 global pharmaceutical company and two Phase 3 products with two biotech companies.

The results come with a proposed merger pending under an Agreement and Plan of Merger dated September 27, 2026 among Lifecore, Lifecore Inc. and Hazel Merger Sub. The company's risk language cites a possible termination fee and the threat to customer and employee relationships.

Management ties its growth case to the two technology transfer programs, which it expects to begin contributing in 2027.

Sources

More on Lifecore Biomedical

All Lifecore Biomedical (LFCR) coverage →